Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

Plain-language summary

This study investigates the value of circulating tumor DNA (ctDNA) in the blood for predicting disease course after the first 6 months of treatment in patients with Waldenström macroglobulinemia. It enrolls patients who meet the diagnostic criteria and require first-line or subsequent-line therapy. It is conducted as a study without a phase designation and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Centre Hospitalier Universitaire, Amiens

Intervention

bone marrow sample, blood sample

Start date

5/16/2022

Estimated completion

7/1/2028

Countries

France

Related genes

Locations

• Amiens, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patient with WM according to diagnostic criteria
* Patients with WM followed in one of the centre of North-Western region.
* Patients requiring first-line or subsequent-line therapy
* Patients agreement for giving informed consent.
* Social insurance system affiliation

Exclusion Criteria:

* Patients with another chronic B-cell malignancy
* patients with other lymphoplasmacytic proliferations
* patients with marginal zone lymphoma.
* Patients with WM and histologic transformation
* Absence of informed consent